Copeptin, a surrogate marker of vasopressin, is associated with accelerated renal function decline in renal transplant recipients

Transplantation

Volumn 88, Issue 4, 2009, Pages 561-567

  Meijer, Esther ^a   Bakker, Stephan J L ^a   De Jong, Paul E ^a   Homan Van Der Heide, Jaap J ^a   Van Son, Willem J ^a   Struck, Joachim ^b   Lems, Simon P M ^a   Gansevoort, Ron T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b BRAHMS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

COPEPTIN; CREATININE; PROTEIN PRECURSOR; UNCLASSIFIED DRUG; VASOPRESSIN;

ADULT; ARTICLE; CREATININE BLOOD LEVEL; DISEASE MARKER; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL;

ADULT; ANIMALS; BIOLOGICAL MARKERS; FEMALE; GLOMERULAR FILTRATION RATE; GLYCOPEPTIDES; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PROSPECTIVE STUDIES; RATS; VASOPRESSINS;

EID: 70349093605     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b11ae4     Document Type: Article

References (32)

1. Bankir L. Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 2001; 51: 372.
2. Robertson GL, Athar S. The interaction of blood osmolality and blood volume in regulating plasma vasopressin in man. J Clin Endocrinol Metab 1976; 42: 613.
3. Bouby N, Ahloulay M, Nsegbe E, et al. Vasopressin increases glomeru-lar filtration rate in conscious rats through its antidiuretic action. J Am Soc Nephrol 1996; 7: 842.
4. Naito A, Hasegawa H, Kurasawa T, et al. Histopathological study of kidney abnormalities in an experimental SIADH rat model and its application to theevaluationofthepharmacologicprofileofVP-343,aselectivevasopres-sin V2 receptor antagonist. Biol Pharm Bull 2001; 24: 897.
5. Bardoux P, Bichet DG, Martin H, et al. Vasopressin increases urinary albumin excretion in rats and humans: Involvement of V2 receptors and the renin-angiotensin system. Nephrol Dial Transplant 2003; 18: 497.
6. Bouby N, Bachmann S, Bichet D, et al. Effect of water intake on the progression of chronic renal failure in the 5/6 nephrectomized rat. Am J Physiol 1990; 258: F973.
7. Bouby N, Hassler C, Bankir L. Contribution of vasopressin to progression of chronic renal failure: Study in Brattleboro rats. Life Sci 1999; 65: 991.
8. Bankir L, Trinh-Trang-Tan MM. Urea and the kidney. In: Brenner BM, ed. The kidney. Philadelphia, Saunders Company 2000, p 637.
9. Okada H, Suzuki H, Kanno Y, et al. Effects of vasopressin V1 and V2 receptor antagonists on progressive renal failure in rats. Clin Sci (Lond) 1994; 86: 399.
10. Sugiura T, Yamauchi A, Kitamura H, et al. High water intake ameliorates tubulointerstitial injury in rats with subtotal nephrectomy: Possible role of TGF-beta. Kidney Int 1999; 55: 1800.
11. Bardoux P, Bruneval P, Heudes D, et al. Diabetes-induced albumin-uria: Role of antidiuretic hormone as revealed by chronic V2 receptor antagonism in rats. Nephrol Dial Transplant 2003; 18: 1755.
12. Preibisz JJ, Sealey JE, Laragh JH, et al. Plasma and platelet vasopressin in essential hypertension and congestive heart failure. Hypertension 1983; 5: I129.
13. Morgenthaler NG, Struck J, Alonso C, et al. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006; 52: 112.
14. Szinnai G, Morgenthaler NG, Berneis K, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007; 92: 3973.
15. Morgenthaler NG, Struck J, Jochberger S, et al. Copeptin: Clinical use of a new biomarker. Trends Endocrinol Metab 2008; 19: 43.
16. Pedersen EB, Danielsen H, Nielsen AH, et al. Relationship between urinary concentrating ability, arginine vasopressin in plasma and blood pressure after renal transplantation. Scand J Clin Lab Invest 1985; 45: 321.
17. de Vries AP, Bakker SJ, van Son WJ, et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004; 4: 1675.
18. van Ree RM, de Vries AP, Oterdoom LH, et al. Abdominal obesity and smoking are important determinants of C-reactive protein in renal transplant recipients. Nephrol Dial Transplant 2005; 20: 2524.
19. Rose BD. Clinical physiology of acid-base and electrolyte disorders. New York, McGraw-Hill 2001.
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461.
21. Zhang X, Hense HW, Riegger GA, et al. Association of arginine vaso-pressin and arterial blood pressure in a population-based sample. J Hypertens 1999; 17: 319.
22. Bhandari SS, Loke I, Davies JE, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009; 116: 257.
23. Perucca J, Bouby N, Valeix P, et al. Sex difference in urine concentration across differing ages, sodium intake, and level of kidney disease. Am J Physiol Regul Integr Comp Physiol 2007; 292: R700.
24. Baumann G, Dingman JF. Distribution, blood transport, and degradation of antidiuretic hormone in man. J Clin Invest 1976; 57: 1109.
25. Hebert LA, Greene T, Levey A, et al. High urine volume and low urine osmolality are risk factors for faster progression of renal disease. Am J Kidney Dis 2003; 41: 962.
26. Bricker NS, Dewey RR, Lubowitz H, et al. Observations on the concentrating and diluting mechanisms of the diseased kidney. J Clin Invest 1959; 38: 516.
27. Cowley AW Jr, Skelton MM, Kurth TM. Effects of long-term vasopres-sin receptor stimulation on medullary blood flow and arterial pressure. Am J Physiol 1998; 275: R1420.
28. Sauter D, Fernandes S, Goncalves-Mendes N, et al. Long-term effects of vasopressin on the subcellular localization of ENaC in the renal collecting system. Kidney Int 2006; 69: 1024.
29. Kreis HA, Ponticelli C. Causes of late renal allograft loss: Chronic allograft dysfunction, death, and other factors. Transplantation 2001; 71: SS5.
30. Chikanza IC, Petrou P, Chrousos G. Perturbations of arginine vaso-pressin secretion during inflammatory stress. Pathophysiologic implications. Ann N Y Acad Sci 2000; 917: 825.
31. Stoiser B, Mortl D, Hulsmann M, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006; 36: 771.
32. Decaux G, Soupart A, Vassart G. Non-peptide arginine-vasopressin antagonists: The vaptans. Lancet 2008; 371: 1624.